Skip to main content

Table 4 Protein marker associations between tumors with/without Amp13q34, CUL4A expression, or TFDP1 expression

From: Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes

Clinical & IHC feature

13q34 Amplification

CUL4A expression

TFDP1 expression

 

Absence

Presence

P

Negative

Positive

P

Negative

Positive

P

Grade

         

1

42 (32.1)

0

0.002*

26 (40.6)

10 (19.2)

0.010*

12 (32.4)

27 (33.3)

NS*

2

40 (30.5)

0

 

19 (29.7)

13 (25.0)

 

11 (29.7)

22 (27.2)

 

3

49 (37.4)

8 (100)

 

19 (29.7)

29 (55.8)

 

14 (37.8)

32 (39.5)

 

ER

         

Negative

56 (35.4)

8 (88.9)

0.002

30 (36.6)

29 (48.3)

NS

24 (46.2)

35 (38.0)

NS

Positive

102 (64.6)

1 (11.1)

 

52 (63.4)

31 (51.7)

 

28 (53.8)

57 (62.0)

 

PR

         

Negative

68 (47.2)

8 (88.9)

0.018

30 (43.5)

37 (62.7)

0.034

20 (48.8)

47 (52.3)

NS

Positive

76 (52.8)

1 (11.1)

 

39 (56.5)

22 (37.3)

 

21 (51.2)

42 (47.7)

 

BCL2

         

Negative

82 (56.9)

8 (88.9)

0.082

37 (53.6)

42 (71.2)

0.047

29 (70.7)

52 (58.4)

NS

Positive

62 (43.1)

1 (11.1)

 

32 (46.4)

17 (28.8)

 

12 (29.3)

37 (41.6)

 

Ki-67

         

0-5%

68 (47.2)

1 (11.1)

< 0.001*

35 (50.7)

22 (37.3)

NS*

22 (53.7)

35 (39.3)

NS*

6-25%

56 (38.9)

1 (11.1)

 

24 (34.8)

20 (33.9)

 

13 (31.7)

32 (36.0)

 

> 25%

20 (13.9)

7 (77.8)

 

10 (14.5)

17 (28.8)

 

6 (14.6)

22 (24.7)

 

EGFR

         

Negative

181 (90.0)

4 (40.0)

< 0.001

122 (91.7)

57 (80.3)

0.024

94 (91.3)

89 (85.6)

NS

Positive

20 (10.0)

6 (60.0)

 

11 (8.3)

14 (19.7)

 

9 (8.7)

15 (14.4)

 

Cadherin P

         

Negative

128 (92.1)

3 (33.3)

< 0.001

63 (95.5)

46 (79.3)

0.011

37 (94.9)

74 (86.0)

NS

Positive

11 (7.9)

6 (66.6)

 

3 (4.5)

12 (20.7)

 

2 (5.1)

12 (14.0)

 

G-Catenin

         

Negative

106 (79.1)

4 (44.4)

0.031

59 (86.8)

43 (75.4)

NS

36 (90.0)

69 (78.4)

NS

Positive

28 (20.9)

5 (55.5)

 

9 (13.2)

14 (24.6)

 

4 (10.0)

19 (21.6)

 

Cyclin D1

         

Negative

67 (47.2)

8 (88.9)

0.018

32 (47.1)

27 (46.6)

NS

17 (42.5)

42 (47.7)

NS

Positive

75 (52.8)

1 (11.1)

 

36 (52.9)

31 (53.4)

 

23 (57.5)

46 (52.3)

 

Cyclin E

         

Negative

103 (72.5)

2 (22.2)

0.004

50 (73.5)

34 (58.6)

0.090

32 (80.0)

53 (60.2)

0.043

Positive

39 (27.5)

7 (77.8)

 

18 (26.5)

24 (41.4)

 

8 (20.0)

35 (39.8)

 

Cyclin B1

         

Negative

111 (80.4)

4 (44.4)

0.024

57 (86.4)

40 (70.2)

0.045

37 (92.5)

61 (72.6)

0.010

Positive

27 (19.6)

5 (55.6)

 

9 (13.6)

17 (29.8)

 

3 (7.5)

23 (27.4)

 

RB

         

Negative

33 (23.9)

6 (66.7)

0.011

12 (18.2)

14 (24.1)

NS

11 (27.5)

15 (17.4)

NS

Positive

105 (76.1)

3 (33.3)

 

54 (81.8)

44 (75.9)

 

29 (72.5)

71 (82.6)

 

E2F6

         

Negative

89 (64.5)

4 (44.4)

NS

39 (59.1)

38 (66.7)

NS

30 (75.0)

47 (56.0)

0.049

Positive

49 (35.5)

5 (55.6)

 

27 (40.9)

19 (33.3)

 

10 (25.0)

37 (44.0)

 

P16

         

Negative

53 (39.0)

7 (77.8)

0.033

24 (36.9)

30 (51.7)

NS

23 (59.0)

31 (36.0)

0.020

Positive

83 (61.0)

2 (22.2)

 

41 (63.1)

28 (48.3)

 

16 (41.0)

55 (64.0)

 

SKP2

         

Negative

66 (46.8)

1 (11.1)

0.043

40 (58.8)

22 (37.9)

0.021

24 (60.0)

40 (46.0)

NS

Positive

75 (53.2)

8 (88.9)

 

28 (41.2)

36 (62.1)

 

16 (40.0)

47 (54.0)

 

Survivin

         

Negative

97 (70.8)

1 (11.1)

0.001

49 (72.1)

35 (61.4)

NS

30 (75.0)

57 (64.8)

NS

Positive

40 (29.2)

8 (88.9)

 

19 (27.9)

22 (38.6)

 

10 (25.0)

31 (35.2)

 

CK5

         

Negative

133 (86.4)

3 (33.3)

0.001

74 (90.2)

43 (72.9)

0.011

42 (82.4)

77 (82.8)

NS

Positive

21 (13.6)

6 (66.6)

 

8 (9.8)

16 (27.1)

 

9 (17.6)

16 (17.2)

 

CK8

         

Negative

28 (19.9)

7 (77.8)

0.001

12 (17.6)

17 (29.3)

NS

7 (17.5)

24 (27.0)

NS

Positive

113 (80.1)

2 (22.2)

 

56 (82.4)

41 (70.7)

 

33 (82.5)

65 (73.0)

 

Vimentin

         

Negative

109 (79.0)

3 (33.3)

0.006

53 (77.9)

41 (70.7)

NS

32 (80.0)

63 (72.4)

NS

Positive

29 (21.0)

6 (66.6)

 

15 (22.1)

17 (29.3)

 

8 (20.0)

24 (27.6)

 
  1. ER = Estrogen Receptor; PR = Progesterone Receptor; CK = cytokeratin. RB = retinoblastoma gene protein.
  2. Markers statistically significant in at least one of the tumor group comparisons are shown. P values ≤ 0.10 are depicted, in bold those statistically significant (P ≤ 0.05). NS = non-significant. P values were calculated by Fisher's Exact Test, except histological grade and Ki-67 analyses that were done with Pearson's Chi square (*).
  3. Other markers were also analyzed (such as HER2) but gave no significant associations.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us